Design Therapeutics, Inc. (DSGN) earnings date
Mar 9, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 16 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Mon, Aug 3, 2026 | before open | 34 | 8-K |
| Q1 FY2026 | Tue, Apr 28, 2026 | after close | 28 | 8-K |
| Q4 FY2025 | Mon, Mar 9, 2026 | after close | 68 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | after close | 36 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | after close | 37 | 8-K |
| Q4 FY2024 | Mon, Mar 10, 2025 | before open | 69 | 8-K |
What they guided beta
| Q3 FY2026 | "Clinical readouts expected in 2027 will help guide these programs as we pursue our vision for the GeneTAC ® platform: to address the underlying causes of serious genetic diseases and deliver meaningful benefits for patients.”" exhibit |
| Q3 FY2026 | "Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027." exhibit |
| Q3 FY2026 | "Design anticipates reporting data from this trial in 2027." exhibit |
| Q3 FY2026 | "Fuchs Endothelial Corneal Dystrophy (FECD): A Phase 2 biomarker trial of DT-168 is ongoing to evaluate safety, tolerability and corneal endothelium biomarkers in FECD patients who are scheduled for corneal transplant surgery, with data expected in 2027." exhibit |
| Q2 FY2026 | "Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1" exhibit |
| Q2 FY2026 | "Next Steps and Expected Milestones: Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027." exhibit |
| Q2 FY2026 | "Design anticipates reporting data from this study in 2027." exhibit |
| Q2 FY2026 | "Data is now expected in 2027 due to a delay in the anticipated supply of DT-168 blow-fill-seal eye droppers." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/DSGN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/DSGN
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/DSGN/"><img src="https://veritasdata.dev/embed/DSGN.svg" alt="DSGN earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/DSGN/)
Script
<script async src="https://veritasdata.dev/embed/DSGN.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/DSGN"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.